Pfizer and MannKind announced Tuesday that they entered into a collaborative agreement under which certain Exubera patients with a continuing medical need for inhaled insulin will be switched to MannKind's Technosphere. Clinical data released Tuesday on the experimental compound demonstrated that the treatment met the primary endpoint in a late-stage study involving patients with type 1 diabetes.
The decision comes as Pfizer gradually transitions Exubera patients off its product, which was discontinued in October 2007 due to low sales.
Under the collaboration, Pfizer said it will reimburse some of MannKind's costs relating to the transition.
To read more Top Story articles, click here.